Exploring the use of immunomethylomics in the characterization of depressed patients: A proof-of-concept study
Brain, Behavior, and Immunity · 2025-01 · 123 · 597-605
DOI: 10.1016/j.bbi.2024.09.026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, Behavior, and Immunity, 2025-01. Verfasst von Evelien Van Assche und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of Münster, Münster, Germany. Hauptthemen laut MEDLINE: Major Depressive Disorder, DNA Methylation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: HORIZON EUROPE European Research Council, European College of Neuropsychopharmacology.
Abstract (Originalsprache)
Alterations in DNA methylation and inflammation could represent valid biomarkers for the stratification of patients with major depressive disorder (MDD). This study explored the use of DNA-methylation based immunological cell-type profiles in the context of MDD and symptom severity over time. In 119 individuals with MDD, DNA-methylation was assessed on whole blood using the Illumina Infinium MethylationEPIC 850 k BeadChip. Quality control and data processing, as well as cell type estimation was conducted using the RnBeads package. The cell type composition was estimated using epigenome-wide DNA methylation signatures, applying the Houseman method, considering six cell types (neutrophils, natural killer cells (NK), B cells, CD4+ T cells, CD8+ T cells and monocytes). Two cytokines (IL-6 and IL-1β) and hsCRP were quantified in serum. We performed a hierarchical cluster analysis on the six estimated cell-types and tested the differences between these clusters in relation to the two cytokines and hsCRP, depression severity at baseline, and after 6 weeks of treatment (celecoxib/placebo + vortioxetine). We performed a second cluster analysis with cell-types and cytokines combined. ANCOVA was used to test for differences across clusters. We applied the Bonferroni correction. After quality control, we included 113 participants. Two clusters were identified, cluster 1 was high in CD4+ cells and NK, cluster 2 was high in CD8+ T-cells and B-cells, with similar fractions of neutrophils and monocytes. The clusters were not associated with either of the two cytokines and hsCRP, or depression severity at baseline, but cluster 1 showed higher depression severity after 6 weeks, corrected for baseline (p = 0.0060). The second cluster analysis found similar results: cluster 1 was low in CD8+ T-cells, B-cells, and IL-1β. Cluster 2 was low in CD4+ cells and natural killer cells. Neutrophils, monocytes, IL-6 and hsCRP were not different between the clusters. Participants in cluster 1 showed higher depression severity at baseline than cluster 2 (p = 0.034), but no difference in depression severity after 6 weeks. DNA-methylation based cell-type profiles may be valuable in the immunological characterization and stratification of patients with MDD. Future models should consider the inclusion of more cell-types and cytokines for better a prediction of treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, University of Münster, Münster, Germany.
- Department of Medicine and Surgery, Kore University of Enna, Enna, Italy.
- Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy.
- Department of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Cagliari, Italy.
- Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; Genetics Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
- Department of Psychiatry, University of Münster, Münster, Germany; Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Melbourne, Australia; The Florey Institute of Neuroscience and Mental H…
Förderung
- HORIZON EUROPE European Research Council
- European College of Neuropsychopharmacology
Zitieren
APA
Van Assche, E., Hohoff, C., Su Atil, E., Wissing, S. M., Serretti, A., Fabbri, C., Pisanu, C., Squassina, A., Minelli, A., European College of Neuropsychopharmacology (ECNP) Pharmacogenomics & Transcriptomics Network, & Baune, B. T. (2025). Exploring the use of immunomethylomics in the characterization of depressed patients: A proof-of-concept study. Brain, Behavior, and Immunity, 123, 597-605. https://doi.org/10.1016/j.bbi.2024.09.026
Vancouver
Van Assche E, Hohoff C, Su Atil E, Wissing SM, Serretti A, Fabbri C, et al. Exploring the use of immunomethylomics in the characterization of depressed patients: A proof-of-concept study. Brain, Behavior, and Immunity. 2025;123:597-605. doi:10.1016/j.bbi.2024.09.026
BibTeX
@article{VanAssche2025,
author = {Van Assche, Evelien and Hohoff, Christa and Su Atil, Ecem and Wissing, Sophia M and Serretti, Alessandro and Fabbri, Chiara and Pisanu, Claudia and Squassina, Alessio and Minelli, Alessandra and European College of Neuropsychopharmacology (ECNP) Pharmacogenomics & Transcriptomics Network, European College of Neuropsychopharmacology (ECNP) Pharmacogenomics & Transcriptomics Network and Baune, Bernhard T},
title = {Exploring the use of immunomethylomics in the characterization of depressed patients: A proof-of-concept study},
journal = {Brain, Behavior, and Immunity},
year = {2025},
volume = {123},
pages = {597--605},
doi = {10.1016/j.bbi.2024.09.026}
}
EUVIMED